Abstract Body

In patients with liver cirrhosis (LC), hepatic venous pressure gradient (HVPG) is the most accurate predictor of liver-related outcomes. Little is known about the effects of therapy (Rx) with DAA on HVPG in patients with HCV-related LC. We assessed changes in HVPG following SVR after DAA -Rx in HCV- monoinfected patients (HIV-) and HIV/HCV- coinfected patients (HIV+) with LC.

Prospective study (4 centers) with patients initiating all-oral DAA Rx between during Jan-Dec 2015. HVPG was measured at baseline and 48 wk after completion of Rx. Inclusion criteria: i) Compensated LC (c-LC) or decompensated LC (d-LC) defined as prior clinical decompensation or Child-Pugh score > 6; ii) clinically significant portal hypertension (CSPH) defined as an HVPG ≥ 10 mmHg; iii) achievement of SVR; iv) no Rx with non-selective betaß-blockers initiated during the study period. Main endpoint: reduction in HVPG to < 10 mmHg. Secondary outcome: decrease in HVPG ≥ 20% or reduction in HVPG to ≤ 12 mm Hg (goal associated with reduced liver complications in patients with variceal bleeding undergoing pharmacological treatment of portal hypertension).

Of 44 patients with LC and paired HVPG measurements, 34 met the 4 inclusion criteria. Main characteristics: median age 53 yr; 22 males, 21 HIV+, 18 previously treated, 17 with d-LC; median MELD score 8; median liver stiffness (LS) 34 kPa. HVPG decreased from 16.5 (IQR 14.4-18.0) at baseline to 14.0 (IQR 10.0 -– 15.0) mmHg at wk 48; (P<.001) (Figure); with a median decrease of 3.1 (IQR 2.0-4.9) mm Hg. No significant differences in the decrease in HVPG decline were observed between HIV- and HIV+. The main outcome endpoint was achieved by 6 patients (18%) and was more frequent in c-LC than in d-LC (35.3 % vs 0 %; P=0.018). The secondary endpoint was achieved by 16 patients (47%); 10 with c-LC (58.8%) and 6 with d-LC (35.3%); P=.303. Of note, HVPG increased from baseline in 4 patients (11.8%). The spearman rho correlation coefficient between changes in HVPG and changes in LS was 0.237, P=.191.

Our findings suggest that, in the medium term, SVR after DAA Rx in patients with LC and CSPH is associated with a decrease in HVPG that is sufficient to reduce the risk of liver complications. However, the frequent persistence of CSPH despite SVR, especially in patients with more advanced disease, indicates a persistent risk of decompensation. The correlation between change in LS and reduction in HVPG was very weak.